THERAPEUTICSMD REPORTS FIRST QUARTER 2014 RESULTS Management to Host Conference Call at 4:30 EDT Today Boca Raton, FL

TherapeuticsMD, Inc. 8-K

THERAPEUTICSMD REPORTS FIRST QUARTER

Management to Host Conference Call at

Boca Raton, FL, May 5, 2014 -

TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's health care company, ("TherapeuticsMD," the "Company,"

"we," or "our") today announced results for the quarter ended March 31, 2014.

First Quarter 2014 Highlights:

Robert G. Finizio, Co-Founder and Chief

Executive Officer, stated, "This has been a busy and exciting quarter for us, highlighted by advancements in clinical trials

for our principal hormone therapy drug candidates. Our two largest commercial opportunities are our investigational combination

estradiol and progesterone (E+P) therapy for treatment of vasomotor symptoms in menopausal women, and estradiol VagiCap for VVA.

We remain on track to complete enrollment this fall in the E+P phase 3 trial, where enrollment is strong and patient retention

is positive. Pending a successful trial, the U.S. Food and Drug Administration's (FDA) approval of our E+P drug candidate, we will

be well positioned as a first-mover in this multi-billion dollar market to introduce and capitalize on what could be the first

safe and effective bioidentical combination hormone therapy product for menopausal women."

"We are equally excited about the

opportunity in VVA. This market more than doubled over the last five years to $1.1 billion in 2013 without any generic options.

Our phase 3 VVA clinical trial is designed to assess the ability of our estradiol VagiCap, which leverages our solubilized lipid-based

technology to achieve new, lower effective doses that could potentially reduce or eliminate systemic exposure to estradiol. Our

goal is to bring to market an innovative VVA drug candidate with a focus on a positive qualitative user experience for menopausal

women, while achieving an improved therapeutic profile." continued Mr. Finizio.

"Our progesterone-only drug candidate

for the treatment of secondary amenorrhea is currently undergoing a phase 3 clinical trial, called the SPRY trial. This clinical

trial has faced recruiting challenges. To remedy these challenges, we are meeting with the FDA in early June 2014 to discuss potential

changes to our inclusion and exclusion criteria."

"In summary, an increasingly receptive

regulatory environment, our promising product pipeline and strong cash position all are contributing to a positive outlook for

the Company and we look forward to our ongoing progress in the important field of women's health care," Mr. Finizio

First Quarter Results

Net revenue for the first quarter of 2014

totaled $2.8 million compared with net revenue of $1.5 million for the prior year quarter. The increase of approximately $1.3 million,

or 84%, was directly attributable to an increase in the number of physicians writing prescriptions for our prenatal products, the

increased productivity of our sales force, and an increase in the average net sales price of our product. Cost of goods sold increased

by $450,000, or 118%, for the three months ended March 31, 2014 compared with the prior year quarter.

Research and development expenses increased

to $5.9 million for the first quarter of 2014 compared with $1.6 million for the first quarter of 2013 because of the development

of our hormone therapy drug candidates and related clinical trials.

Sales, general, and administrative expenses

increased to $5.0 million for the first quarter of 2014 compared with $4.5 million for the first quarter of 2013. As a result,

our operating loss was $9.0 million for the first quarter of 2014 compared with $4.9 million for the first quarter of 2013.

Other non-operating expenses decreased

by approximately $1.2 million for the first quarter of 2014 compared with the comparable quarter in 2013. This decrease was primarily

a result of a decrease in interest expense.

As a result, net loss for the first quarter

of 2014 was $9.2 million, or $0.06 per basic and diluted share, compared with a net loss of $6.4 million, or $0.06 per basic and

diluted share, for the first quarter of 2013.

As previously announced, today Robert G.

Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright,

Chief Financial Officer, will host a conference

call, which may include forward-looking statements, to review the financial results as follows:

An audio replay will be available on-demand

shortly after the completion of the call until May 26, 2014 at 11:59 p.m. EDT at www.therapeuticsmd.com and by dialing

800-633-8284 in the U.S. and Canada, or 402-977-9140 for international callers. The access code for all callers is 21714227.

About Hormone Therapy

Hormone therapy (HT) is the

administration of hormones to supplement a lack of naturally occurring hormones. HT options include natural,

bioidentical, and non-bioidentical (conjugated) hormones. HT is projected to be the largest growth segment in the overall

women's health market. The potential market for pharmacy-compounded, bioidentical HT products is estimated to be

approximately $1.5 billion per year.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a

women's health care company focused on developing and commercializing products targeted exclusively for women. We

manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and

cosmetics, under our vitaMedMD and BocaGreenMD brands. We are currently developing advanced hormone therapy

pharmaceutical drug candidates designed to alleviate the symptoms of and reduce the health risks resulting from

menopause-related hormone deficiencies. We are also evaluating various other potential indications for

our hormone therapy technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian

failure. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com,

and www.bocagreenmd.com.

vitaMedMD , TherapeuticsMD ,

and BocaGreenMD are registered trademarks of TherapeuticsMD, Inc.

Except for the historical information

contained herein, the matters set forth in this press release, including statements relating to future events or performance, including

statements regarding the results of TX-004HR clinical trial; the Company's performance; the progress of the Company's

principal hormone therapy drug candidates; the Company's belief that its combination 17 -estradiol and progesterone

(E+P) and estradiol VagiCap are the Company's two largest commercial opportunities; the progress of enrollment in the Company's

E+P Phase 3 trial; the Company's belief that it will be well positioned as a first-mover in the [$1.5 billion] market

to introduce and capitalize on what could be the first safe and effective bioidentical combination hormone therapy drug product

for menopausal women; the Company's assessment of its opportunity in the VVA market and the increase in the size of the VVA

market; the design of the Company's Phase 3 VVA clinical trial; the attributes and potential benefits of VagiCap; the Company's

goal of bringing to market an innovative VVA drug candidate with a focus on a positive qualitative user experience for menopausal

women, while achieving an improved therapeutic profile; the status of enrollment in the Company's progesterone-only clinical

trial and the challenges facing this clinical trial; the results of the meeting with the FDA and any subsequent changes to the

inclusion and exclusion criteria in the SPRY Trial; the Company's belief that an increasingly receptive regulatory environment,

its promising pipeline and strong cash position are contributing to a positive outlook for the Company; the impact of the number

of physicians writing prescriptions for the Company's prenatal products, the increased productivity of the Company's

sales force, an increase in the average net sales price of the Company's products; projected growth and the size of the potential

market for pharmacy-compounded, bioidentical HT products; and the Company's current product pipeline and hormone technology

that the Company is evaluating are forward-looking statements within the meaning of the "safe harbor" provisions of

the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that

may cause actual results to differ materially, including but not limited to: timely and successful completion of clinical studies

and the results thereof; challenges and costs inherent in product marketing; the risks and uncertainties associated with economic

and market conditions; risks and uncertainties associated with the Company's business and finances in general; and other

risks detailed in the Company's filings with the U.S. Securities and Exchange Commission including its annual report on Form

10-K filed on March 5, 2014, reports on Form 10-Q and Form 8 K, and other such filings. These forward-looking statements are

based on current information that may change. Investors are cautioned not to place undue reliance on these forward-looking statements,

which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary

statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances